Elutia (ELUT) Cash from Operations Growth (3y) (2022 - 2026)

Elutia (ELUT) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 4.78%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 9.30%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 1.51%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 22.35%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -48.14%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 50.11%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 0.50%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -14.75%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Elutia 39.99 Mn 11.50 Mn 1.80 Mn -14.72%

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.72%
Dec 31, 2025 -67.87%
Sep 30, 2025 19.29%
Jun 30, 2025 8.42%
Mar 31, 2025 -6.51%
Dec 31, 2024 -24.27%
Sep 30, 2024 -3.42%
Jun 30, 2024 -76.56%
Mar 31, 2024 20.08%
Dec 31, 2023 -19.16%
Sep 30, 2023 -60.94%
Jun 30, 2023 15.72%
Mar 31, 2023 -19.36%
Dec 31, 2022 -26.79%